Form 8-K - Current report:
SEC Accession No. 0001193125-25-267934
Filing Date
2025-11-06
Accepted
2025-11-06 06:02:14
Documents
12
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d280681d8k.htm   iXBRL 8-K 53732
  Complete submission text file 0001193125-25-267934.txt   170737

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20251106.xsd EX-101.SCH 2897
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20251106_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20251106_pre.xml EX-101.PRE 11292
14 EXTRACTED XBRL INSTANCE DOCUMENT d280681d8k_htm.xml XML 3643
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 251455910
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)